Viral Vectors in Gene Therapy

Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80, 148, 10.1016/j.ymgme.2003.08.016

McCormack, 2004, Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency, N. Engl. J. Med., 350, 913, 10.1056/NEJMra032207

Garrigue, 2008, Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1, J. Clin. Investig., 118, 3132, 10.1172/JCI35700

Schiedner, 1998, Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity, Nat. Genet., 18, 180, 10.1038/ng0298-180

Wang, 2012, Biodistribution and safety assessment of bladder cancer specific oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice, Curr. Gene Ther., 12, 67, 10.2174/156652312800099599

Wei, 2017, Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses, Cell. Physiol. Biochem., 41, 2383, 10.1159/000475909

Samulski, 2014, AAV-mediated gene therapy for research and therapeutic purposes, Annu. Rev. Virol., 1, 427, 10.1146/annurev-virology-031413-085355

Park, 2008, Cancer gene therapy using adeno-associated virus vectors, Front. Biosci., 13, 2653, 10.2741/2872

Mingozzi, 2013, Immune responses to AAV vectors: Overcoming barriers to successful gene therapy, Blood, 122, 23, 10.1182/blood-2013-01-306647

Grieger, 2005, Packaging capacity of adeno-associated virus serotypes: Impact of larger genomes on infectivity and postentry steps, J. Virol., 79, 9933, 10.1128/JVI.79.15.9933-9944.2005

McClements, 2017, Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes, Yale J. Biol. Med., 90, 611

Epstein, 2005, HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy, Curr. Gene Ther., 5, 445, 10.2174/156652305774329285

Holmes, 2000, A multi-mutant herpes simplex virus vector has minimal cytotoxic effects on the distribution of filamentous actin, alpha-actinin and a glutamate receptor in differentiated PC-12 cells, J. Neurovirol., 6, 33, 10.3109/13550280009006380

Schambach, 2016, Retroviral vectors for cancer gene therapy, Recent Results Cancer Res., 209, 17, 10.1007/978-3-319-42934-2_2

Hu, 2000, Design of retroviral vectors and helper cells for gene therapy, Pharmacol. Rev., 52, 493

Vigna, 2000, Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy, J. Gen. Med., 2, 308, 10.1002/1521-2254(200009/10)2:5<308::AID-JGM131>3.0.CO;2-3

Kay, 2001, Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics, Nat. Med., 7, 33, 10.1038/83324

Lundstrom, 2016, Self-replicating RNA viral vectors in vaccine development and gene therapy, Future Virol., 11, 345, 10.2217/fvl-2016-0028

Lundstrom, 2017, Latest trends in cancer gene therapy applying viral vectors, Future Virol., 12, 667, 10.2217/fvl-2017-0070

Csatary, 1999, Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MHT-68/H), Anticancer Res., 19, 635

Lundstrom, K. (2018). New frontiers in oncolytic viruses: Optimizing and selecting for virus strains with improved efficacy. Biol. Targets Ther., in press.

Crainic, 1989, An insight into poliovirus biology, Adv. Exp. Med. Biol., 257, 61, 10.1007/978-1-4684-5712-4_8

Bradley, 2014, Applications of coxsackievirus A21 in oncology, Oncolytic Virother., 3, 47, 10.2147/OV.S56322

Kwak, 2003, Poxviruses as vectors for cancer immunotherapy, Curr. Opin. Drug Discov. Devel., 6, 161

Zeh, 2002, Development of a replication-selective oncolytic proxvirus for the treatment of human cancers, Cancer Gene Ther., 9, 1001, 10.1038/sj.cgt.7700549

Mastrangelo, 2002, Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors, Cancer Gene Ther., 9, 1013, 10.1038/sj.cgt.7700538

Niemann, 2017, Oncolytic viruses: Adenoviruses, Virus Genes, 53, 700, 10.1007/s11262-017-1488-1

Nagasato, 2017, A tumor-targeting adenovirus with high gene-transduction efficiency for primary pancreatic cancer and ascites cells, Anticancer Res., 37, 3599

Yamamoto, 2017, Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors, Cancer Med., 6, 2385, 10.1002/cam4.1185

Emdad, L., Das, S.K., Wang, X.Y., Sarkar, D., and Fisher, P.B. (2017). Cancer Terminator Viruses (CVT): A better solution for viral-based therapy of cancer. J. Cell. Physiol.

Zhang, 2017, Recent advances in preclinical developments using adenovirus hybrid vectors, Hum. Gene Ther., 28, 833, 10.1089/hum.2017.140

Panek, 2017, Hitting the nail on the head: Combining oncolytic adenovirus-mediated virotherapy and immodulation for the treatment of glioma, Oncotarget, 8, 89391, 10.18632/oncotarget.20810

Illingworth, 2017, Preclinical safety studies of Enadenotucirev, a chimeric group B human-specific oncolytic virus, Mol. Ther. Oncolytics, 5, 62, 10.1016/j.omto.2017.03.003

Sinnett, 2017, Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome, Discov. Med., 24, 153

Pfister, E., Dinardo, N., Mondo, E., Borel, F., Conroy, F., Fraser, C., Gernoux, G., Han, X., Hu, D., and Johnson, E. (2017). Artificial miRNAs reduce human mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington’s disease. Hum. Gene Ther.

Guggino, 2017, A preclinical study in Rhesus macaques for cystic fibrosis to assess gene transfer and transduction by AAV1 and AAV5 with a dual-luciferase reporter system, Hum. Gene Ther. Clin. Dev., 28, 145, 10.1089/humc.2017.067

Yue, 2016, Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy, Expert Opin. Orphan Drugs, 4, 169, 10.1517/21678707.2016.1124039

Kodippili, K., Hakim, C.H., Pan, X., Yang, H.T., Yue, Y., Zhang, Y., Shin, J.H., Yang, N.N., and Duan, D. (2017). Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb Mini-Dystrophin gene in the canine model. Hum. Gene Ther.

Greig, 2017, Characterization of adeno-associated viral vector-mediated human Factor VIII gene therapy in hemophilia A mice, Hum. Gene Ther., 28, 292, 10.1089/hum.2016.128

Thankur, 2016, Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals, Mol. Cell. Neurosci., 72, 46, 10.1016/j.mcn.2016.01.006

Chattopadhyay, 2013, Targeted delivery of growth factors by HSV-mediated gene transfer for peripheral neuropathy, Curr. Gene Ther., 13, 315, 10.2174/156652321305131212123237

Eissa, 2017, Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials, Front. Oncol., 7, 149, 10.3389/fonc.2017.00149

Yang, 2016, Treatment of colon cancer with oncolytic herpes simplex virus in preclinical models, Gene Ther., 23, 450, 10.1038/gt.2016.15

Gaspar, 2005, Gene therapy for severe combined immunodeficiences, Expert Opin. Biol. Ther., 5, 1175, 10.1517/14712598.5.9.1175

Fraefel, 2015, Novel immunotherapeutic approaches in targeting dendritic cells with virus vectors, Discov. Med., 20, 111

Kusabuka, 2016, Highly efficient gene transfer using a retroviral vector into murine T cells for preclinical chimeric antigen receptor-expressing T cell therapy, Biochem. Biophys. Res. Comm., 473, 73, 10.1016/j.bbrc.2016.03.054

Huang, 2015, Intravenous administration of retroviral replicating vector, Toca 511, demonstrates efficacy in orthotopic immune-competent mouse glioma model, Hum. Gene Ther., 26, 82, 10.1089/hum.2014.100

Stein, 2013, From bench to bedside: Preclinical evaluation of a self-activating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease, Hum. Gene Ther. Clin. Dev., 24, 86, 10.1089/humc.2013.019

Calabria, 2016, Safe and efficient gene therapy of pyruvate kinase deficiency, Mol. Ther., 24, 1187, 10.1038/mt.2016.87

Hutson, 2014, Lentiviral vector-mediated RNA silencing in the central nervous system, Hum. Gene Ther. Methods, 25, 14, 10.1089/hgtb.2013.016

Sapru, 2006, Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi, Exp. Neurol., 198, 382, 10.1016/j.expneurol.2005.12.024

Horvath, 2011, Knockdown of GAD87 protein levels normalizes neuronal activity in a rat model of Parkinson’s disease, J. Gene Med., 13, 188, 10.1002/jgm.1555

Singer, 2005, Targeting BACE1 with siRNAs ameliorates Alzheimer’s disease neuropathology in a transgenic model, Nat. Neurosci., 8, 1343, 10.1038/nn1531

Piedrahita, 2010, Silencing of CDK5 reduces neurofibrillary tangles in Alzheimer’s mice, J. Neurosci., 30, 13966, 10.1523/JNEUROSCI.3637-10.2010

Ringpis, G.E., Shimizu, S., Arokium, H., Camba-Colón, J., Carroll, M.V., Cortado, R., Xie, Y., Kim, P.Y., Sahakyan, A., and Lowe, E.L. (2012). Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS ONE, 7.

Peterson, 2016, Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS, Mol. Ther. Methods Clin. Dev., 3, 16007, 10.1038/mtm.2016.7

Lundstrom, K. (2017). Oncolytic alphaviruses in cancer Immunotherapy. Vaccines, 5.

Ketola, 2008, Replication competent Semliki Forest virus prolongs survival in experimental lung cancer, Int. J. Cancer, 123, 1704, 10.1002/ijc.23646

Roche, 2010, Semliki Forest virus-mediated gene therapy of the RG2 rat glioma, Neuropathol. Appl. Neurobiol., 36, 648, 10.1111/j.1365-2990.2010.01110.x

Ylosmaki, 2013, Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting, J. Virol, 87, 335, 10.1128/JVI.01940-12

Lin, 2014, Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers, Proc. Natl. Acad. Sci. USA, 111, E4504, 10.1073/pnas.1408759111

Smeenk, 2009, A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy, Gene Ther., 16, 190, 10.1038/gt.2008.169

Clarke, 2006, Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector, Springer Semin. Immunopathol., 28, 239, 10.1007/s00281-006-0042-3

Muik, 2014, Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency, Cancer Res., 74, 3567, 10.1158/0008-5472.CAN-13-3306

Zhang, 2016, Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFNβ-NIS, Hum. Gene Ther. Clin. Dev., 27, 111, 10.1089/humc.2016.061

LeBlanc, 2013, Safety studies on intravenous administration of onclolytic recombinant vesicular stomatitis virus in purpose-bread beagle dogs, Hum. Gene Ther. Clin. Dev., 24, 174, 10.1089/humc.2013.165

Hastie, 2012, Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer, J. Gen. Virol., 93, 2529, 10.1099/vir.0.046672-0

Reddi, 2012, Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy, Cancer Gene Ther., 19, 659, 10.1038/cgt.2012.47

Hartkopf, 2013, Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase, Gynecol. Oncol., 130, 362, 10.1016/j.ygyno.2013.05.004

Lampe, 2013, An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis, Gene Ther., 20, 1033, 10.1038/gt.2013.28

Lange, 2013, A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma, Hum. Gene Ther., 24, 554, 10.1089/hum.2012.136

Niu, 2015, Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model, Technol. Cancer Res. Treat., 14, 607, 10.7785/tcrt.2012.500414

Chai, Z., Zhang, P., Fu, F., Zhang, X., Liu, Y., Hu, L., and Li, X. (2014). Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virol. J., 11.

Bai, 2014, Genetically engineered Newcastle disease virus expressing interleukin-12 and TNF-related and apoptosis-inducing ligand for cancer therapy, Cancer Ther. Biol., 15, 1226, 10.4161/cbt.29686

Wu, 2017, Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy, Eur. J. Pharmacol., 802, 85, 10.1016/j.ejphar.2017.02.042

Kim, 2012, Coxsackievirus B3 used as a gene therapy vector to express functional FGF2, Gene Ther., 19, 1159, 10.1038/gt.2011.201

Shafren, 2004, Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21, Clin. Cancer Res., 10, 53, 10.1158/1078-0432.CCR-0690-3

Skelding, 2009, Systemic targeting of metastatic human breast xenografts by Coxsackievirus A21, Breast Cancer Res. Treat., 113, 21, 10.1007/s10549-008-9899-2

Skelding, 2012, Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride, Investig. New Drugs, 30, 568, 10.1007/s10637-010-9614-0

Berry, 2008, Potent oncolytic activity of human enteroviruses against human prostate cancer, Prostate, 68, 577, 10.1002/pros.20741

Zhang, 2015, Vaccinia virus, a promising new therapeutic agent for pancreatic cancer, Immunotherapy, 7, 1249, 10.2217/imt.15.90

Madan, 2007, PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma, Expert Opin. Biol. Ther., 7, 543, 10.1517/14712598.7.4.543

Ady, 2015, Oncolytic gene therapy with recombinant vaccinia virus strain GLV-2b372 efficiently kills hepatocellular carcinoma, Surgery, 158, 331, 10.1016/j.surg.2015.03.044

Mansfield, 2016, Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer, Gene Ther., 23, 357, 10.1038/gt.2016.5

Potts, 2017, Deletion of F4L (ribonucleotide recductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models, EMBO Mol. Med., 9, 638, 10.15252/emmm.201607296

Ricordel, 2017, Cowpox virus: A new and armed oncolytic poxvirus, Mol. Ther. Oncolytics, 7, 1, 10.1016/j.omto.2017.08.003

Salazar, 2017, Phase 1 study of intravenous administration of the chimeric enadenotucirev in patients undergoing primary tumor resection, J. Immunother. Cancer, 5, 71, 10.1186/s40425-017-0277-7

Chapin, J.C., and Monahan, P.E. (2017). Gene therapy for hemophilia. BioDrugs.

Spencer, 2016, State of the art: Gene therapy of haemophilia, Haemophilia, 22, 66, 10.1111/hae.13011

Dodd, 2014, Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells, J. Gene Med., 16, 131, 10.1002/jgm.2769

Cloughesy, 2016, Phase I trial of vocimagine amiroretrorepvec and 5-fluorocytosine for recurrent high-grade glioma, Sci. Transl. Med., 8, 341ra75, 10.1126/scitranslmed.aad9784

(2018, May 14). Available online: https://clinicaltrials.gov/ct2/show/NCT02414165/.

Guo, 2016, Phase I study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers, Mol. Ther., 24, 1492, 10.1038/mt.2016.101

Petrulio, 2006, Development of the PANVAC-VF vaccine for pancreatic cancer, Expert. Rev. Vaccines, 5, 9, 10.1586/14760584.5.1.9

(2018, April 27). Therion Reports Results of Phase 3 panvac-vf Trial and Announces Plans for Company Sale. PR Newswire 28 June. Available online: www.prnewswire.com.

Riedmann, 2014, Human vaccines & immunotherapeutics: News, Hum. Vaccin. Immunother., 10, 1773, 10.4161/hv.36241

Patel, 2016, Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astocytoma or gliosarcoma, Hum. Gene Ther. Clin. Dev., 27, 69, 10.1089/humc.2016.031

Markert, 2009, Phase 1b trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM, Mol. Ther., 17, 199, 10.1038/mt.2008.228

Markert, 2014, A phase I trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses, Mol. Ther., 22, 1048, 10.1038/mt.2014.22

Waters, 2017, Rationale and design of a phase I clinical trial to evaluate HSV G207 alone or with a single radiation dose in children with progressive or recurrent malignant supratentorial brain tumors, Hum. Gene Ther. Clin. Dev., 28, 7, 10.1089/humc.2017.002

Slovin, 2013, A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer, Vaccine, 31, 943, 10.1016/j.vaccine.2012.11.096

Lundstrom, 2005, Biology and applications of alphaviruses in gene therapy, Gene Ther., 12, S92, 10.1038/sj.gt.3302620

Tayeb, 2015, Therapeutic potential of oncolytic Newcastle disease virus: A critical review, Oncolytic Virother., 4, 49

Schirrmacher, 2005, Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory, Cancer Immunol. Immunother., 54, 587, 10.1007/s00262-004-0602-0

Voit, 2003, Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease, J. Dtsch. Dermatol. Ges., 1, 120, 10.1046/j.1610-0387.2003.02014.x

Pecora, 2002, Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers, J. Clin. Oncol., 20, 2251, 10.1200/JCO.2002.08.042

Liang, 2003, Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract, World J. Gastroenterol., 9, 495, 10.3748/wjg.v9.i3.495

Bodor, 2015, CCR5 targeted cell therapy for HIV and prevention of viral escape, Viruses, 7, 4186, 10.3390/v7082816

Qin, 2003, Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5, Proc. Natl. Acad. Sci. USA, 100, 183, 10.1073/pnas.232688199

(2017, May 14). Available online: http://fdaaa.trialstracker.net/trial/ NCT01734850/.

Pandha, 2015, Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21, in advanced cancer patients, J. Immunother. Cancer, 3, P341, 10.1186/2051-1426-3-S2-P341

Andtbacka, 2015, Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment, J. Immunother. Cancer, 3, P343, 10.1186/2051-1426-3-S2-P343

Silk, 2017, Abstract CT026: Phase 1b study of intratumoral coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial, Cancer Res., 77, CT026, 10.1158/1538-7445.AM2017-CT026

Alton, 2017, Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis, Thorax, 72, 137, 10.1136/thoraxjnl-2016-208406

Pikkarainen, 2008, Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications, Curr. Mol. Pharmacol., 1, 13, 10.2174/1874467210801010013

Liu, 2008, Gene therapy progress and prospects cancer: Oncolytic viruses, Gene Ther., 15, 877, 10.1038/gt.2008.72

Zhang, 2018, The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic, Hum. Gene Ther., 29, 160, 10.1089/hum.2017.218

Fukuhara, 2016, Oncolytic virus therapy: A new era of cancer treatment at dawn, Cancer Sci., 107, 1373, 10.1111/cas.13027

Kaufman, 2010, Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma, Ann. Surg. Oncol., 17, 718, 10.1245/s10434-009-0809-6

(2017, April 21). Available online: https://european-biotechnology.com/up-to-date/latest-news/news/uniqure-withdraws-eur1m-drug-glybera-from-market.html.

Heo, 2013, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat. Med., 19, 329, 10.1038/nm.3089

Ramesh, 2006, CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer, Clin. Cancer Res., 12, 305, 10.1158/1078-0432.CCR-05-1059

Gollamudi, 2010, REO-001: Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients in advanced solid tumors, Investig. New Drugs, 28, 641, 10.1007/s10637-009-9279-8

Ino, 2010, Clinical development of a third-generation HSV-1 (G47Δ) for malignant glioma, Gene Ther. Regul., 5, 101, 10.1142/S1568558610000185

Beitelshees, 2017, Pressing diseases that represent promising targets for gene therapy, Discov. Med., 24, 313

Zhou, 2016, Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes, Mol. Ther., 24, 1090, 10.1038/mt.2016.55

Gandara, 2018, Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to Good Manufacturing Practice, Hum. Gene Ther. Methods, 29, 1, 10.1089/hgtb.2017.098

Srinivasakumar, 2001, HIV-1 vector systems, Somat. Cell Mol. Genet., 26, 51, 10.1023/A:1021074613196

Suwanmanee, 2017, Toward personalized gene therapy: Characterizing the host genetic control of lentiviral-vector-mediated hepatic gene delivery, Mol. Ther. Methods Clin. Dev., 5, 83, 10.1016/j.omtm.2017.03.009

Lee, 2017, Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine, Genes Dis., 4, 43, 10.1016/j.gendis.2017.04.001

Tsuji, 2018, Rapid construction of antitumor T-cell receptor vectors from frozen tumors for engineered T-cell therapy, Cancer Immunol. Res., 6, 594, 10.1158/2326-6066.CIR-17-0434